|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||51.11 - 52.37|
|52 Week Range||27.94 - 53.50|
|PE Ratio (TTM)||30.30|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.57|
For $50 and the cost of shipping on Amazon , you could get the same protection against chemical weapons that Gaithersburg's Emergent BioSolutions sells to protect soldiers on the ground. If you hit purchase, you would get what's called a reactive skin decontamination lotion kit. Inside are a sponge and specialized lotion cleared by the U.S. Food and Drug Administration to remove or neutralize such chemical warfare agents as sarin and mustard gas from the skin in a single step.
GAITHERSBURG, Md., Feb. 28, 2018-- Emergent BioSolutions Inc. today announced a contract award by the Centers for Disease Control and Prevention valued at $26 million over 12 months for the continued supply ...
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS GAITHERSBURG, Md. and LYON, France, February 26, 2018 - Emergent BioSolutions Inc. (NYSE: ...
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.
The Gaithersburg, Maryland-based company said it had net income of 67 cents per share. Earnings, adjusted for non-recurring costs, were 74 cents per share. The results surpassed Wall Street expectations. ...
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Emergent BioSolutions Inc. (NYSE: EBS ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 5:00 PM Eastern ...
Emergent BioSolutions Inc’s (NYSE:EBS) most recent return on equity was a substandard 12.20% relative to its industry performance of 16.59% over the past year. EBS’s results could indicate a relativelyRead More...
SAN DIEGO, CA / ACCESSWIRE / February 12, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of NYSE: EBS shares against Emergent Biosolutions Inc. over ...
GAITHERSBURG, Md., Feb. 08, 2018-- Emergent BioSolutions Inc. will host a conference call on Thursday, February 22, 2018 at 5:00 pm to discuss the financial results for the fourth quarter and full twelve ...
Nationally, among the biggest losers as of Monday was Seattle-based radio technology and software maker Impinj Inc. (PI), which saw its stock price plummet 45 percent to $11.94 between Jan. 29 and Feb. 5. The slide follows a stretch that saw U.S. stocks hit historic highs amid investor excitement over strong corporate earnings reports, a growing economy and the passage of a business-friendly tax bill. Last month, the stalwart Dow Jones Industrial Average took just seven days to add 1,000 points and surpass 26,000 for the first time in its history. Gina Martin Adams, chief equity strategist for Bloomberg Intelligence, said investors were overly optimistic in 2017 amid a steady stream of strong corporate earnings reports.
Several D.C.-area publicly traded companies saw their stock prices hit in recent days as U.S. stock exchanges saw a widespread selloff Friday, continuing into Monday trading. In the worst stock market ...
NEW YORK, Jan. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cavco ...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EBS. Over the last one-month, outflows of investor capital in ETFs holding EBS totaled $4.05 billion.
GAITHERSBURG, Md., Jan. 08, 2018-- Emergent BioSolutions Inc. today announced preliminary unaudited 2017 financial results and guidance for 2018.. Daniel J. Abdun-Nabi, president and chief executive officer ...
We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.